周二盘中，中国生物制药（01177）股价大跌5.05%，引发市场关注。这一跌幅反映了当日港股通创新药板块的整体疲软表现。
据悉，港股通创新药ETF（520880）高开低走，盘中跌幅达1.74%，成交额超1.4亿元。该ETF成份股普遍下跌，其中映恩生物-B（09606）跌幅超过7%，中国生物制药和石药集团（01093）分别下跌超过4%和3%。这表明创新药板块正面临较大的短期调整压力。
尽管短期行情波动加大，但分析师仍看好创新药行业的长期发展。华创证券指出，创新药行业正从数量逻辑向质量逻辑转换，进入"产品为王"的阶段。兴业证券也强调，创新药板块景气度可持续，中国创新药企业的全球竞争力持续增强。近期政策利好，如香港特区推动"大湾区临床试验协作平台"建设，以及国家药监局优化创新药临床试验审评审批流程，都有望为行业带来长期利好。投资者需密切关注后市创新药板块的变化趋势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.